Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent On Pending Merger; Stock Up
Indivior Pharmaceuticals (INDV) declared a $8.13 special cash dividend per share, contingent on its merger with Supernus. The dividend applies to shares and equity awards, payable on November 6, 2026, if the merger closes. INDV stock rose 0.38% to $34.35 and is up 5% in pre-market trading.
How this was made
The 30-second read
Why it matters
The special dividend serves as a merger‑completion incentive, likely attracting short‑term buying pressure.
Market read
The announcement creates a clear, time‑bound catalyst for INDV shareholders and traders monitoring the merger.
What to watch
Potential regulatory scrutiny of the merger and the cash position needed to fund the dividend.
Background
Indivior focuses on long‑acting injectable treatments for opioid use disorder and is merging with Supernus Pharmaceuticals.
Ticker impact
Indivior declared a special $8.13 cash dividend payable only if its merger with Supernus closes, prompting a 5% pre‑market price rise.
Potential short‑term rally toward $36‑$38 if merger confirmation appears; downside risk if deal fails.
Dividend is a tangible cash benefit tied to a known merger timeline, creating a clear catalyst for traders.
Market effects
Adds positive sentiment to the specialty pharma/ addiction‑treatment sector as a merger‑related dividend is rare.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact beyond investors tracking the INDV‑Supernus deal.
Counterpoint
If the merger stalls, the dividend is void, and the stock could fall sharply from the current premium.
Key entities
- companyIndivior Pharmaceuticals, Inc.
U.S. specialty pharma announcing the dividend.
- companySupernus Pharmaceuticals, Inc.
Merger partner; dividend contingent on deal closing.
